Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation
- PMID: 36469929
- DOI: 10.7326/L22-0482
Correction: Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation
Erratum for
-
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study.Ann Intern Med. 2022 Nov;175(11):1515-1524. doi: 10.7326/M22-0511. Epub 2022 Nov 1. Ann Intern Med. 2022. PMID: 36315950
Publication types
LinkOut - more resources
Full Text Sources